Lexaria Bioscience (LEXX) Net Income (2017 - 2026)
Lexaria Bioscience (LEXX) posted Net Income of -$2.0 million for Q2 2026, down 37.19% sequentially from -$1.5 million in Q1 2026, and up 47.42% YoY from -$1.4 million in Q2 2025.
Lexaria Bioscience (LEXX) Net Income (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Net Income for 10 years, with the latest figure at -$2.0 million in Q2 2026.
- Quarterly Net Income rose 47.42% year-over-year to -$2.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$7.7 million (up 32.15% YoY) and the FY2025 annual result came in at -$25.3 million, down 53.55% from the prior year.
- Net Income fell to -$2.0 million in Q2 2026 per LEXX's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Net Income peaked at -$748547.0 in Q3 2022 and troughed at -$3.8 million in Q2 2025.
- A 5-year average of -$2.0 million and a median of -$1.9 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2026: Net Income tumbled 5993.46% in 2022, then jumped 47.42% in 2026.
- Over 5 years, Net Income stood at -$1.7 million in 2022, then jumped by 32.38% to -$1.2 million in 2023, then sank by 129.79% to -$2.7 million in 2024, then soared by 40.98% to -$1.6 million in 2025, then declined by 24.76% to -$2.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$2.0 million, -$1.5 million, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1.99 Mn |
| Feb 28, 2026 | -1.45 Mn |
| Nov 30, 2025 | -1.60 Mn |
| Aug 31, 2025 | -2.69 Mn |
| May 31, 2025 | -3.79 Mn |
| Feb 28, 2025 | -2.72 Mn |
| Nov 30, 2024 | -2.71 Mn |
| Aug 31, 2024 | -2.18 Mn |
| May 31, 2024 | -2.72 Mn |
| Feb 29, 2024 | -1.07 Mn |
| Nov 30, 2023 | -1.18 Mn |
| Aug 31, 2023 | -1.12 Mn |
| May 31, 2023 | -2.40 Mn |
| Feb 28, 2023 | -1.35 Mn |
| Nov 30, 2022 | -1.74 Mn |
| Aug 31, 2022 | -748,547.00 |
| May 31, 2022 | -2.47 Mn |
| Feb 28, 2022 | -1.52 Mn |
| Nov 30, 2021 | -2.09 Mn |
| Feb 28, 2021 | -25,000.00 |